Exchange Traded Concepts LLC Has $1.88 Million Stock Position in Ginkgo Bioworks Holdings, Inc. (NYSE:DNA)

Exchange Traded Concepts LLC lowered its holdings in Ginkgo Bioworks Holdings, Inc. (NYSE:DNA) by 47.9% during the fourth quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 191,274 shares of the company’s stock after selling 175,704 shares during the quarter. Exchange Traded Concepts LLC owned 0.33% of Ginkgo Bioworks worth $1,878,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors have also recently added to or reduced their stakes in the company. SG Americas Securities LLC acquired a new stake in Ginkgo Bioworks in the 4th quarter valued at approximately $199,000. Point72 Asia Singapore Pte. Ltd. grew its holdings in Ginkgo Bioworks by 644.5% in the 3rd quarter. Point72 Asia Singapore Pte. Ltd. now owns 32,319 shares of the company’s stock valued at $263,000 after buying an additional 27,978 shares during the last quarter. FNY Investment Advisers LLC lifted its position in shares of Ginkgo Bioworks by 125.6% in the 4th quarter. FNY Investment Advisers LLC now owns 75,966 shares of the company’s stock worth $745,000 after acquiring an additional 42,298 shares during the period. Verition Fund Management LLC bought a new stake in shares of Ginkgo Bioworks in the 3rd quarter worth approximately $792,000. Finally, Algert Global LLC bought a new stake in shares of Ginkgo Bioworks in the 2nd quarter worth approximately $36,000. Institutional investors and hedge funds own 78.63% of the company’s stock.

Ginkgo Bioworks Price Performance

Shares of DNA stock opened at $12.76 on Monday. The stock has a 50 day moving average price of $9.73. Ginkgo Bioworks Holdings, Inc. has a 12 month low of $5.26 and a 12 month high of $64.40. The company has a market cap of $733.44 million, a P/E ratio of -0.98 and a beta of 1.09.

Ginkgo Bioworks Company Profile

Ginkgo Bioworks Holdings, Inc, together with its subsidiaries, develops platform for cell programming in the United States. Its platform is used to program cells to enable biological production of products, such as novel therapeutics, food ingredients, and chemicals derived from petroleum. It serves pharma and biotech, agriculture, industrial and environment, food and nutrition, consumer and technology, and government and defense industries.